¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose measurement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose intolerance
    Æ÷µµ´ç ºÒ³»¼º
  • glucose lactate cycle
    ±Û·çÄÚ¿À½º¶ôÆ®»ê ȸ·Î.
  • glucose level
    Æ÷µµ´çÄ¡<--ÁØÀ§>
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • glucose oxidase
    Æ÷µµ´ç»êÈ­È¿¼Ò
  • glucose oxidase =GOD
    ±Û·çÄÚ¿À½º »êÈ­È¿¼Ò(¡­ß«ûùý£áÈ), ±Û·çÄÚ¿À½º¿Á½Ã ´ÙÁ¦.
  • glucose oxidizer
    Æ÷µµ´ç»êÈ­Á¦
  • glucose oxydase test
    Æ÷µµ´ç»êÈ­È¿¼Ò¹ý.
  • glucose oxydation fermentation test
    Æ÷µµ´ç»êÈ­¹ßÈ¿½ÃÇè.
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glucose
    ±Û·çÄÚ½º, Æ÷µµ´ç.
  • glucose
    Æ÷µµ´ç
  • glucose
    Æ÷µµ´ç
  • glucose 1 phosphate
    ±Û·çÄÚ¿À½º-1-Àλê.
  • glucose 3 phosphatase =G-3-P
    ±Û·çÄÚ¿À½º-3-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase =G-6-P
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦.
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose 6 phosphate
    ±Û·çÄÚ¿À½º-6-Àλê.
  • glucose 6 phosphate dehydrogenase =G 6 PD
    ±Û·çÄÚ¿À½º 6Àλê Å»¼ö ¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½º-6-ÀÎ»ê µ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose 6 phosphate dehydrogenase def
    ±Û·çÄÚ¿À½º-6-Àλê Å»¼ö¼Ò È¿¼Ò°á
  • glucose dehydrogenase
    ±Û·çÄÚ¿À½ºÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çÄÚ¿À½ºµ¥È÷µå·Î°Ô³ªÁ¦.
  • glucose effect
    Æ÷µµ´çÈ¿°ú
  • glucose equivalent
    ±Û·çÄÚ¿À½º´ç·®.
  • glucose fermenter
    Æ÷µµ´ç¹ßÈ¿¼Ò
  • glucose fluctuation
    Æ÷µµ´çº¯µ¿
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CSTM cervical prevertebral soft tissue measurement
E of M error of measurement
HOME Home Observation for Measurement of the Environment
LAM laminectomy; laminin; late ambulatory monitoring; Latin American male; left anterior measurement; le...
meas measurement
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FDG PET 2-(18)fluoro-2-deoxy-D-glucose positron emission tomography
18FDG 2-18F-fluorodeoxy-D-glucose
FDG 18)F]-2-deoxy-2-fluro-D-glucose
[(18)F]FDG 18)F]2-fluoro-2-deoxy-D-glucose
2 DG 2 deoxy-glucose
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
glucose-6-phosphatase hepatorenal glycogenosis Glycogenosis due to glucose-6-phosphatase deficiency, resulting in accumulation of excessive amounts of glycogen of normal chemical structure, particularly in liver and kidney.
Synonym: Gierke's disease, glucose-6-phosphatase hepatorenal glycogenosis, von Gierke's disease.
(05 Mar 2000)
glucose-6-phosphate <biochemistry> Glucose 6-phosphate is a phosphomonoester of glucose that is formed by transfer of phosphate from ATP, catalysed by the enzyme hexokinase.
It is an intermediate both of the glycolytic pathway (next converted to fructose 6 phosphate) and of the NADPH generating pentose phosphate pathway, formed from glucose via hexokinase. However it is not strictly a glycolytic intermediate and it is readily converted to glycogen or oxidized to NADPH.
(10 Oct 1997)
glucose-6-phosphate dehydrogenase <enzyme> An NADP+ enzyme that catalyses the dehydrogenation (oxidation) of d-glucose-6-phosphate to 6-phospho-d-glucono-d-lactone, this reaction initiating the Dickens shunt.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome. Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans.
Synonym: Robison ester dehydrogenase, Zwischenferment.
Acronym: G6PD
(12 Sep 2002)
glucose-6-phosphate dehydrogenase deficiency A deficiency of glucose-6-phosphate dehydrogenase, an enzyme important for maintaining cellular concentrations of reduced nucleotides.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome and there are various polymorphic forms.
Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans. It can also cause anaemia of the newborn, and chronic nonspherocytic haemolytic anaemia.
Inheritance: X-linked.
(12 Sep 2002)
glucose-6-phosphate isomerase <enzyme> An enzyme that catalyses the reversible interconversion of glucose-6-phosphate and fructose-6-phosphate, and is a part of the glycolytic and gluconeogenic pathways. Deficiency of the enzyme, an autosomal recessive trait, results in liver glycogenesis and haemolytic anaemia.
Chemical name: D-Glucose-6-phosphate ketol-isomerase
Registry number: EC 5.3.1.9
(12 Dec 1998)
glucose-6-phosphate translocase <enzyme> A component of EC 3.1.3.9 which transports glucose phosphate into endoplasmic reticulum
Registry number: EC 2.7.-
Synonym: t1 transport protein
(26 Jun 1999)
glucose clamp technique <technique> Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.
(12 Dec 1998)
glucose dehydrogenase <enzyme> Converts beta-d-glucose to d-glucono-d-lactone, transferring hydrogen to NAD+ or NADP+.
Compare: glucose oxidase.
(05 Mar 2000)
glucose dehydrogenases <enzyme> D-glucose:1-oxidoreductases. Catalyses the oxidation of d-glucose to d-glucono-gamma-lactone and reduced acceptor. Any acceptor except molecular oxygen is permitted.
Registry number: EC 1.1.1.
(12 Dec 1998)
glucose effect <biochemistry> The ability of the sugar glucose to block sugar metabolism by keeping the genes which make the enzymes involved in the early steps of sugar metabolism from making those enzymes.
(09 Oct 1997)
glucose-fructose oxidoreductase <enzyme> Isolated from zymomonas mobilis; catalyses the formation of sorbitol and glucono-delta-lactone from glucose and fructose; enzyme contains tightly bound nadp+
Registry number: EC 1.1.99.-
(26 Jun 1999)
glucose intolerance A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases.
(12 Dec 1998)
glucose isomerase <enzyme> An isomerase enzyme which converts the sugar glucose into the sugar fructose. Fructose is a structural isomer of glucose.
(09 Oct 1997)
glucose oxidase <enzyme> An enzyme which converts glucose into gluconic acid and hydrogen peroxide (H2O2). It is used to help diagnose diabetes by determining if glucose is present in the patients urine, if the glucose is present, the hydrogen peroxide produced in the reaction can be detected by reacting it with an indicator to change the colour of the urine.
(09 Oct 1997)
glucose oxidase method <chemical pathology> A highly specific method for measurement of glucose in serum or plasma by reaction with glucose oxidase, in which gluconic acid and hydrogen peroxide are formed.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á